Viatris Sets The Bar Low So There Will Eventually Be A Chance To Grow
Executive Summary
Viatris' 2021 financial guidance was below investor expectations, suggesting a challenging road ahead for the newly formed company.
You may also be interested in...
Viatris Pipeline Progress Includes Eylea, Botox Biosimilars
In its first sales and earnings call, Viatris management updated investors on the development of some key complex generics and biosimilars.
Organon Is Ready To Launch And Makes The Case To Investors
Merck & Co. plans to spin off Organon in June as a diversified health care company focused on women's health, biosimilars and established products.
Up To 9,000 Jobs At Risk As Viatris Kicks Off $1bn Restructuring Scheme
With a goal of reducing its cost base by at least $1bn by 2024, Viatris has delivered plans to significantly restructure its global manufacturing network. Up to 20% of Viatris’ 45,000-strong workforce could be impacted by the initiative which will see the firm close, divest or downsize 15 of its manufacturing plants around the globe.